#ma-acquisition-rumors

#ma-acquisition-rumors

Markets could remain sensitive to the developments in the Middle East. Tensions remain elevated in the region amid continued incidents in the Strait of Hormuz and a failed attempt for a second round of talks this week, undermining prospects for a near-term resolution.

Evoke confirmed it is in discussions with Bally's Intralot S.A. regarding a possible offer for the entire issued and to be issued share capital of the Company at a price of 50 pence per share.

Polymarket is reportedly in advanced talks to raise approximately $400 million in new funding at a post-money valuation of roughly $15 billion, according to a report published by The Information. The round has not been finalized, meaning terms could still change.

The Ether Machine and Dynamix Corporation announced the termination of their Business Combination Agreement, originally signed on July 21, 2025, through a Current Report on Form 8-K filed with the SEC.

Lucid's cost of revenue consistently exceeds total revenue, and shareholder equity collapsed from $3.87 billion in FY 2024 to $717 million in FY 2025.

Mega IPOs like OpenAI and SpaceX are creating a gravity well in the public markets, what that means for smaller companies waiting to go public and whether the IPO pipeline is actually reopening in 2026. They also dig into the growing tension inside software companies as AI agents begin to threaten seat based pricing models and what recent disclosures are quietly admitting about the competitive risks.

Nearly 47.24 million shares are sold short, representing 29.09% of the float, with short interest rising 3.56% since the last report, indicating a bearish sentiment.

From its IPO in 2016 to its peak in late 2024, the stock gained more than 4,000% as it regularly put up revenue growth of 20% or more, and delivered strong profit margins as well. The stock also benefited from a premium valuation. However, over the last year, The Trade Desk has collapsed. The adtech stock has fallen 83% from its peak in late 2024 as the business has slowed to its weakest growth rate ever, except for a brief dip during the pandemic.

The battle for WBD played out amid a pivotal backdrop for Wall Street: a period investment banks hope will mark a full-throated M&A rebound, in which just landing a role on a deal of this size is as useful for one's street cred as actually winning it. Even advisers on the losing side will walk away with hefty fees, boardroom credibility, and proof they belong on the biggest mandates of the coming year.

For decades, the United States stock market has been a juggernaut on the international stage. The US dollar has been - and still is - the de facto currency globally. But for how much longer that will be the case is now looking uncertain. As the New York Times reports, investors are starting to look elsewhere as the Trump administration continues to threaten the independence of its central bank, start a trade war with Europe, and implement self-conflicting monetary policies.

Since expenses for external advisers are not reimbursed if a deal falls through, PE firms wait until they are certain of their interest before engaging costly specialists such as consultants from McKinsey, BCG, or Bain to perform extensive commercial research on the market and the target company.

The ETF holds 50 positions, but the top two dominate in a way that makes the rest almost incidental. Johnson & Johnson carries a 25.4% weight, and Eli Lilly and Company sits at 21.4%. Together they account for roughly 46.8% of the entire fund.